



teamit
RESEARCH

2023 ANNUAL REPORT

 **teamit**
INSTITUTE

Table of contents

Foreword	03
2022 at a glance	05
• European ecosystem.....	06
• 2022 in numbers	07
• Key achievements in 2022	08
• Our areas of expertise.....	09
• Fields of research.....	10
Delivering impact in 2022	11
• Corporate	12
• Communications	13
• EU-funded projects	14
• Teamit Research team.....	21
• Teamit Institute.....	22
Strategic plan	25
What will happen in 2023	26

Foreword



Eva Molero

CEO

At Teamit, we share a vision to enable **impactful science** that improves people's lives. To achieve it, we strive for **excellence and game-changing results**. With this in mind, we kickstart work on our Annual Report each January with a twofold objective. On the one hand, we aim to **inform our stakeholders** about Teamit activities and progression made during the last year. On the other hand, we aim to **reflect on our work**, the achievements accomplished as a team and, equally important, the challenges faced. The **learnings** we pull from this introspective exercise annually **are key to underpinning our progress**.

In hindsight, the consolidation of Teamit in 2022 would have not been possible without the solid foundations laid in the two prior years, including **continuous improvement and innovation**. We are an organisation with a strong growth and **entrepreneurial mindset**. During 2022, we cemented our internal procedures and quality systems, strengthened our team and focused on our long-term strategy.


This eventually translated into Teamit **playing a strategic role in far-reaching European-funded projects and international pharmacoepidemiology studies**, and **entering new scientific areas** such as immunotherapies, medical devices, vaccines, cancer and mental health.

REMEDI4ALL, a Horizon Europe project aimed at writing a new chapter in the repurposing of medicines, kicked off in September 2022, under the leadership of EATRIS (European Advanced Translational Research Infrastructure in Medicine). As a strategic partner, Teamit was key to helping the proposal be successful. Indeed, Teamit is part of the project core team and leads several areas, including management, communications or exploitation, to ensure future impact. **Fibrotarget**, a second Health Cluster proposal focused on developing immunotherapies for inflammatory bowel disease, was also awarded in 2022 and is due to start in 2023.

Our **international vocation** has taken us beyond Europe and as far as New Zealand and Australia (**Global Covid Vaccine Safety study –GCoVS**) and the USA. At the same time, we have reinforced our **connection with the Catalan ecosystem**, working closely with reputable scientific organisations and innovative enterprises such as Institute for Bioengineering of Catalonia (IBEC), Sant Joan de Déu Hospital, Fundació Institut Mar d'Investigacions Mèdiques (IMIM Hospital del Mar), Universitat Pompeu Fabra (UPF), Foundation University Institute for Primary Health Care Research Jordi Gol i Gurina (IDIAPJGol), Vall d'Hebron Institute of Research (VHIR) and Chemotargets.

In hindsight, the consolidation of Teamit in 2022 would have not been possible without the solid foundations laid in the two prior years, including continuous improvement and innovation.

**Consolidation
Strategy
Innovation
Vision**



Teamit professionals have actively **participated in international congresses**—International Conference of Pharmacoepidemiology (ICPE), World Orphan Drugs Congress (WODC), Society for Laboratory Automation and Screening (SLAS), International Society of Pharmacovigilance (ISOP), World Vaccine Congress (WVC)— **presenting their own publications or contributing as experts in panels.** Furthermore, the **increasing number of publications** reflects our strategic contribution to the scientific success of each project and **Teamit’s reputation** in the life sciences ecosystem.

Finally, we have **reinforced the areas of communications and dissemination, innovation and sustainability** of project results, and regulatory expertise to get us closer to realising our vision of **game-changing and impactful science.** To this end, we are currently working on **Teamit’s strategic plan** for the next three years. This will soon be made public.

All in all, we look towards the future with optimism, aware that we hold a responsibility to contributing to better health in Europe and beyond.

Eva Molero
CEO Teamit Research


We have reinforced the areas of communications and dissemination, innovation and sustainability of project results, and regulatory expertise to get us closer to realising our vision of game-changing and impactful science.

2022 at a glance

European ecosystem



We have worked closely with >100 organisations, leading life-science research in Europe, USA and beyond during 2022.



**>100
PARTNERS**



2022 in numbers



Teamit has managed studies and projects worth >140 million € during 2022 and submitted proposals to Horizon Europe and the Innovative Health Initiative (IHI) funding programmes.

7

Pharmacoepidemiology
Studies

113

Partners

6

European-funded
Projects

6

Research Proposals

+140M

Valued at

+20

Employees

Key achievements in 2022

Growing team & expertise

We have reinforced our expertise in strategic management, communication, innovation, sustainability and regulatory science with the incorporation of new team members.

Start of REMEDI4ALL project

Funded by Horizon Europe, REMEDI4ALL kicked off in September to drive forward drug repurposing. TEAMIT has a strategic role in this complex, yet transformative project.

Participation in conferences

We have attended international congresses, conferences, seminars and workshops, giving oral and poster presentations or participating in panel discussions around topics such as public private partnerships, scientific research management and impact.



Back to face to face meetings and events

After two years interacting mainly online, we have been deeply involved in the organisation of in person external events and large consortium meetings across Europe.



RESCEU CLOSING EVENT

BRUSSELS

RESCEU RSV POLICY SUMMIT

BRUSSELS

VAC4EU GAM

BARCELONA

PROMISE GAM

BRUSSELS

REMEDI4ALL GAM

AMSTERDAM

H2O GAM

BASEL

PREMIER GAM

MILAN

H2O OBSERVATORIES LAUNCH EVENT

BRUSSELS

Our areas of expertise




STRATEGY & INNOVATION

Innovation in Research
Data management
Business development



EU PROJECTS

EU Proposals
Project management
Stakeholder Engagement



PARTNERSHIPS


Regulatory Science
Research Networks
Real-World Evidence



IMPACT

Communications & dissemination
Exploitation & Sustainability
Policy

Fields of research



Repurposing of Medicines



Innovative Clinical Designs



Patient Reported Outcomes



Environmental Risks of Medicines



Respiratory Syncytial Virus (RSV) Immunisation



Vaccine Monitoring



Pharmacoepidemiology



Delivering impact in 2022

Corporate



Martina Spadetto
HEAD OF MANAGEMENT

The Corporate area has focused on responding quickly to Teamit’s rapid expansion.

In practical terms, there was a clear need for a larger office space to accommodate the growing team. Our search for a different location in the stunning Sant Pau Art Nouveau site, which had already played host to our home since 2020, was successful. In April 2022, we relocated to our new offices in an adjacent pavilion managed by the Barcelona Health Hub (BHH).

Furthermore, to ensure the quality and smooth execution of Teamit’s activities, we developed policies and procedures, renewing our ISO 9001 certification and reinforcing onboarding practices. We also fostered team spirit, self-management and creativity through several activities such as a cooking workshop and a painting masterclass.

Apart from the afore mentioned, we continued our activity as external consultants in different areas such as data sharing in collaborative research and patient engagement. Within these roles, we collaborated with the European Federation of Pharmaceutical Industries and Associations (EFPIA) and Fundació Sant Joan de Dèu (FSJD).

Finally, via an internal and participatory process, employees at Teamit conceived the strategic plan for 2023-2025 to fortify the company’s positioning within the European Research Network. Its implementation will start in the second quarter of 2023.



- ✓ **Strategic plan 2023-2025**
- ✓ **New talent and team building**
- ✓ **ISO 9001
Renewal** 
- ✓ **Participation in Barcelona Health Hub activities**
- ✓ **Consultancy services**

Communications






Gisela Pairó
HEAD OF COMMUNICATIONS

Our vision of improving health outcomes by supporting the advancement of life sciences calls for impactful science. The Communications area contributes to underpinning this strategy.

In 2020, we established the area of communications to complement Teamit's existing expertise in innovation and exploitation and contribute to maximising societal, scientific and economic impact across our vast portfolio of research projects and activities.

Three years later, this investment has paid dividends. We have developed and consolidated a strong base of expertise in communications and dissemination, supporting innovation and sustainability with positive results. Our proven track record, mainly as leaders of communications, dissemination and exploitation in European Union (EU) funded projects, has translated into playing leading roles in the design and implementation of comprehensive and promising strategies. This past year, Teamit led communications of several EU-funded projects (RESCEU, PROMISE, EU-PEARL and REMEDI4ALL), contributed to H2O's communication strategy, and participated in drafting the Impact section of various research proposals.

- ✓ **REMEDI4ALL**
Development of the communication strategy and initial tools
- ✓ **EU-PEARL**
Planning for the sustainability phase
- ✓ **PROMISE** 
Project & RSV Awareness
- ✓ **RESCEU**  
Visibility and broad dissemination of results
Closing event & RSV Policy Summit
- ✓ **TEAMIT**
Corporate Communications

EU-funded projects



Nuria Machin

HEAD OF EU-FUNDED PROJECTS

Undoubtedly, 2022 has seen the expansion of the R&D Project’s Unit, including the addition of REMEDI4ALL, an ambitious and complex Horizon Europe (HE) funded project on drug repurposing.

Furthermore, a second project related to inflammatory bowel disease (IBD) with HE funding is due to start in Q2 2023.

On the other side of the spectrum, the RESCEU project came to an end during 2022. Teamit played an active role in this project focused on advancing research and immunisation solutions for respiratory syncytial virus (RSV). This initiative delivered an impactful, substantial body of research literature and successful outcomes, largely contributing to widening the social impact in future RSV prevention.

Regarding the development of new projects, we have engaged in preparing far-reaching proposals on early detection of cancer, adolescent mental health and medical devices. Some were already submitted in 2022, whilst others will be presented during 2023.

Furthermore, we have focused on resource planning for further growth in 2023. To this end, new team members with expertise in the scientific management of research have joined the team. Past learnings, best practices and standard operating procedures underpin the steady maturing of the R&D Projects area.

Beyond the domains of scientific project management and communications and sustainability, novel opportunities arose in 2022 for new areas of expertise (including policy and training) and fields of research.

- ✓ **6 proposals presented**
- ✓ **Start of REMEDI4ALL**
- ✓ **Finalisation of RESCEU**
- ✓ **Implementation of 6 EU-funded projects**





OUR CONTRIBUTION:

**Support Scientific
Coordination
Project Management
Communications
& Dissemination**

RESCEU project aims to develop robust evidence on RSV disease burden and economic impact; create a sustainable Europe-wide multidisciplinary, multi-stakeholder community from academia, public health, scientific societies, patient organisations, regulatory agencies and industry; and provide infrastructure to perform future pivotal trials for RSV vaccines and therapeutics.

 **University of Edinburgh (UEDIN), SANOFI**


 **18 Partners**

 **25 M**

 **2017–2022**

Project highlights

- ✓ **RSV Science Policy Summit** held in Brussels to disseminate final project results on disease burden amongst policy-makers
- ✓ **Project closing event**
- ✓ **+ 50 scientific publications**



PROMISE

Preparing for RSV Immunisation
and Surveillance in Europe

OUR CONTRIBUTION:


Support Scientific
Coordination
Project Management
Dissemination
Exploitation

PROMISE builds on RESCEU's (Respiratory Syncytial Virus Consortium in Europe) achievements to continue advancing scientific knowledge on RSV to better inform public health strategies and to support the development and introduction of novel immunisations tools and therapeutics against this potentially deadly virus in the paediatric and elderly populations.

 **University of Edinburgh (UEDIN),
University of Utrecht (UMCU), SANOFI**

 **22 Partners**

 **7 M**

 **2021-2024**

Project highlights


- ✓ **Survey** targeting RSV-vulnerable populations in order to further understand barriers towards RSV immunisation
- ✓ **Engagement with** regional immunisation technical advisory groups (**NITAGs**) to provide local/national and regional data
- ✓ **RSV awareness week** in November 2022 to inform about the impact of RSV on patients and health systems
- ✓ Development of PROMISE **infant case-control study**




OUR CONTRIBUTION:

**Support Scientific
Coordination
Project Management
Communication**

EU-PEARL's mission is to shape the future of clinical trials by promoting a new paradigm of **collaborative platform trials**, where patients play a bigger part in trial designs and outcomes.

 **Vall d'Hebron Research Institute (VHIR)
& JANSSEN Pharmaceutica**

 **36 Partners**

 **25,6 M**

 **2019–2023**

Project highlights

- ✓ **Successful Midterm Review**
by the European Commission
- ✓ **Development of a generic Master protocol template**
for Integrated Research Platforms
- ✓ **2nd stakeholder workshop** organised to foster debate
with key stakeholders, including regulators,
researchers and patients
- ✓ **Sustainability plan** and project KPIs approved




OUR CONTRIBUTION:


**Project Management
Support Scientific
Coordination,
Communications
and Sustainability**

H2O is actively contributing to **strengthen the patients' voice in health care** by incorporating their reported outcomes in treatment decisions.

 **Medical University of Vienna (MUW)
& Takeda Pharmaceuticals**

 **24 Partners**

 **22 M**

 **2020–2025**

- ✓ **Partnership with key regulators & HTA agencies**
to secure public sector support
- ✓ **Selection of Core Outcome Sets** through a consensus process (Delphi) to promote standardisation and collaboration with ICHOM
- ✓ **1st National Observatory launched in Spain**
- ✓ **Netherlands & Austria National Observatories**
launched in the autumn



PREMIER

PRIORITISATION AND RISK EVALUATION
OF MEDICINES IN THE ENVIRONMENT


OUR CONTRIBUTION:

**Project
Management
Communications
and Dissemination
Support Scientific
Coordination
& Sustainability**

The **PREMIER** project is contributing to a more sustainable future by proactively managing the environmental impact of medicines.

 **Radboud University (RU), AstraZeneca**

 **25 Partners**

 **9,7 M**

 **2020–2026**

- ✓ Publication of **first scientific paper**: “*Development of a generalised physiologically based kinetic (PBK) model for fish*”
- ✓ **Publication of GREENER criteria** for the development of sustainable pharmaceuticals and consequent selection as editors choice due to its public interest
- ✓ **Third release of the PREMIER database** and digital assessment system made available to project partners
- ✓ First **face-to-face General Assembly Meeting** organised in October 2022 in Milan



OUR CONTRIBUTION:


Support Scientific
Coordination
Project Management
Training
Communication

REMEDi4ALL is building a sustainable European innovation platform to enhance the repurposing of medicines for all.

 **EATRIS**

 **24 Partners**


 **25 M**

 **2022-2027**

Project highlights

- ✓ **Project launch** and kick off meeting in Amsterdam
- ✓ Development of the **training and capacity building programme**
- ✓ Establishment of **advisory boards** & paving the way for a global drug repurposing community
- ✓ **Mapping inventory** of projects, initiatives, organisations to aid internalisation.

Teamit Research team



Our company welcomes the best minds and skill sets to help us reach our vision of better health outcomes.



Maica Llaveró
PROJECT MANAGER



Berta Gumí
PROJECT MANAGER



Saira Ramasastry
SUSTAINABILITY EXPERT



Berta Español Salvat
PROJECT MANAGER



Claudia Garcia
PROJECT MANAGER



Mili Cavalieri
PROJECT MANAGER ASSISTANT



Dubravka Kruljac
PROJECT MANAGER



Annaël Le Bihan
PROJECT MANAGER



Zofia Marczevska
JUNIOR COMMUNICATIONS
OFFICER



Ivette Corominas
EVENTS COORDINATOR

Teamit Institute



Gianmarco Di Mauro
HEAD OF PARTNERSHIPS

The area of Partnerships fully consolidated in 2022, expanding its sphere of action and broadly disseminating the impact of its activities.

We expanded our work on real-world evidence (RWE) with the kick-off of 4 new pharmacoepidemiology and pharmacovigilance studies within VAC4EU (EMA, CDC and pharma-funded). We also strengthened our role in supporting VAC4EU both in the business development and governance of the network.

An achievement of which we are particularly proud is the active dissemination of our work across 3 international conferences (ICPE; WODC; SLAS; ISOP; WVC). Additionally, we also generated a new opportunity in regulatory science, building upon our previous experience.

Furthermore, we optimised this unit by implementing an agile internal structure and welcoming two new employees to reinforce our team.

All in all, 2022 represented a tremendous year in term of results and achievements. All the objectives established were reached and exceeded within the VAC4EU framework. As for the EU-ADR Alliance, we remain steadfast in our commitment to executing active services. In this sense, we have identified the need of new actions to adapt to the everchanging context of RWE studies for the pharmacovigilance of medicinal products.



- ✓ ISOP, ICPE, WVC
- ✓ 7 Studies
- ✓ Hosted VAC4EU General Assembly Meeting



Real world data access providers from 9 EU countries

Over 40 European and worldwide partners, from academia, industry, regulatory agencies and health authorities

Our work in 2021-2022 has generated 5 publications



ICPE 2022
 AUGUST 24-28, 2022
 BELLA CENTER COPENHAGEN
 COPENHAGEN, DENMARK

Teamit Institute team

Every colleague plays a strategic and pivotal role in the success of this Teamit Research spin-off.



Natasha Yefimenko
SENIOR STUDY MANAGER



Katica Boric
STUDY MANAGER



Fabio Riefolo
STUDY MANAGER




Dana Danieleescu
STUDY MANAGER



Elena Palà
JUNIOR STUDY MANAGER

Strategic plan




Raimon Cardelús
INNOVATION MANAGER

In 2022 TEAMIT has been **reflecting on its trajectory** through a series of **participatory workshop**. As a result of this exercise, we defined the strategic challenge: ***“How might we fully achieve TEAMIT’s potential?”***

Strategic Plan 2023-2025

To be implemented
or rolled out in 2023
under 3 strategic areas:



What will happen in 2023



We step into 2023, optimistic about how we continue to advance our vision of collaborative research for better health outcomes. As we begin to finalise and implement our ambitious yet rooted strategic plan over the next three years, we can expect to uphold our normal activities whilst building open our team’s capabilities and experience. Current and new challenges will come and go, but our tenacity, creativity and hard work will ensure that impactful science translates into real solutions.

Visit our [website](#) to get the latest updates. Follow us on [Twitter](#) and [LinkedIn](#).

START of Fibrotarget



END of EU-PEARL



START of Strategic plan 2023-2025




END of 2 EMA studies


Thank you!

Teamit Research

Barcelona Health Hub
Recinte Modernista de Sant Pau
c/ Sant Antoni Maria Claret, 167
08025 Barcelona (Spain)
T +34 930 180 163

www.teamitresearch.com

 @TeamItResearch

 @team-it-research

